Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials

    Clinical Journal of the American Society of Nephrology Date published:

  • Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level pooled analysis from CANVAS Program and CREDENCE trial

    Journal of Cardiac Failure Date published:

  • Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk

    European Journal of Clinical Pharmacology Date published:

  • Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies

    Current Heart Failure Reports Date published:

  • Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study

    Diabetes Research and Clinical Practice Date published:

  • Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR

    Kidney International Reports Date published:

  • Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression

    Clinical Journal of the American Society of Nephrology Date published:

  • Assessing patterns of chronic kidney disease care in Australian primary care: a retrospective cohort study of a national general practice dataset

    The Lancet Regional Health - Western Pacific Date published:

  • Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD

    Kidney International Reports Date published:

  • Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Systolic Blood Pressure and Pulse Pressure in Heart Failure

    Journal of the American College of Cardiology Date published:

  • Risk-directed management of chronic kidney disease

    Nature Reviews Nephrology Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

    European Journal of Heart Failure Date published:

  • Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials

    Clinical Kidney Journal Date published:

  • Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published: